Ziprasidone hydrochloride is an atypical antipsychotic medication used to treat schizophrenia and bipolar disorder. It is a dopamine and serotonin antagonist, meaning it blocks the activity of these neurotransmitters in the brain. The synthesis of ziprasidone hydrochloride involves several steps, including the reaction of a substituted benzophenone derivative with an appropriately functionalized piperazine derivative. Ziprasidone hydrochloride has been shown to be effective in reducing psychotic symptoms, including hallucinations, delusions, and disorganized thinking. It is also effective in treating mood episodes associated with bipolar disorder. The importance of ziprasidone hydrochloride lies in its ability to provide relief from the debilitating symptoms of schizophrenia and bipolar disorder. It is studied to understand its mechanism of action, its efficacy in treating different mental health conditions, and its safety and tolerability.'
ziprasidone hydrochloride hydrate : The hydrochloride hydrate salt of ziprasidone. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 60853 |
| CHEMBL ID | 1375743 |
| SCHEMBL ID | 122875 |
| MeSH ID | M0326878 |
| Synonym |
|---|
| cp-880591 |
| cp 88,059-1 |
| 2h-indol-2-one, 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-, monohydrochloride, monohydrate |
| 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-2-indolinone monohydrochloride, monohydrate |
| ziprasidone hydrochloride monohydrate |
| cp-88059-01 |
| me-2112 |
| cp-88,059-1 |
| ziprasidone hydrochloride hydrate |
| ziprasidone hydrochloride (usp) |
| 138982-67-9 |
| ziprasidone hydrochloride hydrate (jan) |
| D01939 |
| geodon (tn) |
| NCGC00186050-01 |
| 5-(2-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)-6-chloroindolin-2-one hydrochloride hydrate |
| AKOS015961662 |
| 216x081oru , |
| ziprasidone hydrochloride [usan:usp] |
| unii-216x081oru |
| HY-17407 |
| ziprasidone (hydrochloride monohydrate) |
| CS-1198 |
| FT-0600387 |
| LP01025 |
| ziprasidone hydrochloride [usp-rs] |
| ziprasidone hydrochloride [usp monograph] |
| ziprasidone hydrochloride [mart.] |
| ziprasidone hydrochloride [orange book] |
| ziprasidone hydrochloride [vandf] |
| 2h-indol-2-one, 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-, hydrochloride, hydrate (1:1:1) |
| ziprasidone hydrochloride monohydrate [ep monograph] |
| ziprasidone hydrochloride monohydrate [mi] |
| ziprasidone hydrochloride hydrate [jan] |
| ziprasidone hydrochloride [who-dd] |
| CCG-222329 |
| SCHEMBL122875 |
| NCGC00261710-01 |
| tox21_501025 |
| CHEMBL1375743 |
| ziprasidone hcl hydrate |
| DTXSID00160855 |
| mfcd00921885 |
| ziprasidone hydrochloride, united states pharmacopeia (usp) reference standard |
| ZCBZSCBNOOIHFP-UHFFFAOYSA-N |
| ziprasidone for system suitability 1, european pharmacopoeia (ep) reference standard |
| ziprasidone hydrochloride monohydrate, >=98% (hplc), solid |
| ziprasidone hydrochloride monohydrate, european pharmacopoeia (ep) reference standard |
| ziprasidone for system suitability 2, european pharmacopoeia (ep) reference standard |
| ziprasidone hydrochloride monohydrate 1.0 mg/ml in methanol (as anhydrous free base) |
| J-007206 |
| ziprasidone hcl monohydrate |
| Q27114865 |
| AS-16359 |
| BCP29919 |
| ziprasidone hydrochloride monohydrate;cp88059; cp-88059; cp 88059; cp-88,059; cp-88,059-01 |
| 2h-indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, hydrochloride, hydrate (1:1:1) |
| 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one;hydrate;hydrochloride |
| T71751 |
| 5-(2-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)-6-chloroindolin-2-onehydrochloridehydrate |
| ziprasidone hydrochloride monohydrate- bio-x |
| BZ164577 |
| 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one, hydrochloride, hydrate (1:1:1) |
| 5-(2-(4-(BENZO[D]ISOTHIAZOL-3-YL)PIPERAZIN-1-YL)ETHYL)-6-CHLOROINDOLIN-2-ONE HYDROCHLORIDE MONOHYDRATE |
| Class | Description |
|---|---|
| hydrochloride | A salt formally resulting from the reaction of hydrochloric acid with an organic base. |
| hydrate | An addition compound that contains water in weak chemical combination with another compound. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 17.5574 | 0.0041 | 10.8903 | 31.5287 | AID493106; AID493107 |
| Fumarate hydratase | Homo sapiens (human) | Potency | 35.4813 | 0.0030 | 8.7949 | 48.0869 | AID1347053 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 0.2818 | 0.0316 | 37.5844 | 354.8130 | AID504865 |
| regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 16.8336 | 0.5318 | 15.4358 | 37.6858 | AID504845 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 21.5932 | 0.0015 | 30.6073 | 15,848.9004 | AID1224819; AID1224820; AID1224821; AID1224823 |
| polyprotein | Zika virus | Potency | 35.4813 | 0.0030 | 8.7949 | 48.0869 | AID1347053 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 10.6213 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) | Homo sapiens (human) | Potency | 23.2809 | 0.0165 | 25.3078 | 41.3999 | AID504836; AID602332 |
| D(1A) dopamine receptor | Homo sapiens (human) | Potency | 0.0479 | 0.0224 | 5.9449 | 22.3872 | AID488982; AID488983 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 79.4328 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 0.2668 | 0.0060 | 26.1688 | 89.1251 | AID488953 |
| ras-related protein Rab-9A | Homo sapiens (human) | Potency | 58.0479 | 0.0002 | 2.6215 | 31.4954 | AID485297 |
| serine/threonine-protein kinase mTOR isoform 1 | Homo sapiens (human) | Potency | 23.2809 | 0.0037 | 8.6189 | 23.2809 | AID2660 |
| Ataxin-2 | Homo sapiens (human) | Potency | 31.6228 | 0.0119 | 12.2221 | 68.7989 | AID588378 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| negative regulation of receptor internalization | Ataxin-2 | Homo sapiens (human) |
| regulation of translation | Ataxin-2 | Homo sapiens (human) |
| RNA metabolic process | Ataxin-2 | Homo sapiens (human) |
| P-body assembly | Ataxin-2 | Homo sapiens (human) |
| stress granule assembly | Ataxin-2 | Homo sapiens (human) |
| RNA transport | Ataxin-2 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| RNA binding | Ataxin-2 | Homo sapiens (human) |
| epidermal growth factor receptor binding | Ataxin-2 | Homo sapiens (human) |
| protein binding | Ataxin-2 | Homo sapiens (human) |
| mRNA binding | Ataxin-2 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| cytoplasm | Ataxin-2 | Homo sapiens (human) |
| Golgi apparatus | Ataxin-2 | Homo sapiens (human) |
| trans-Golgi network | Ataxin-2 | Homo sapiens (human) |
| cytosol | Ataxin-2 | Homo sapiens (human) |
| cytoplasmic stress granule | Ataxin-2 | Homo sapiens (human) |
| membrane | Ataxin-2 | Homo sapiens (human) |
| perinuclear region of cytoplasm | Ataxin-2 | Homo sapiens (human) |
| ribonucleoprotein complex | Ataxin-2 | Homo sapiens (human) |
| cytoplasmic stress granule | Ataxin-2 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1347167 | Vero cells viability qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347152 | Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347169 | Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347058 | CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7 | Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
| AID1347149 | Furin counterscreen qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347168 | HepG2 cells viability qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347161 | Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347057 | CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7 | Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
| AID1347151 | Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347059 | CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7 | Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
| AID1347410 | qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library | 2019 | Cellular signalling, 08, Volume: 60 | A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening. |
| AID1347405 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347153 | Confirmatory screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504836 | Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation | 2002 | The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16 | Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells. |
| AID588349 | qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay | |||
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588378 | qHTS for Inhibitors of ATXN expression: Validation | |||
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 4 (44.44) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (49.41) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||